vTv Therapeutics Inc. VTVT
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
vTv Therapeutics Inc. (VTVT) is a healthcare company listed in the US with a market value of about $79M. In the twelve months to September 30, 2026 it had revenue of $37M and net income of -$8M, a net margin of -20.8%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -103%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 95% below the current price.
About vTv Therapeutics
vTv Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $2M in 2014 to $1M in 2024, a decline of about 4.1% a year. It was profitable in 0 of the last 10 years in our data.
Score: 1.0 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37M | $0 | $1M | $0 | $2M | $4M | $6M | $3M | $12M | $291000 | $634000 |
| Net income | -$8M | -$27M | -$18M | -$20M | -$19M | -$13M | -$8M | -$13M | -$8M | -$16M | -$16M |
| Free cash flow | — | — | -$25M | -$19M | -$16M | -$19M | -$18M | -$23M | -$27M | -$45M | -$48M |
| EPS (diluted) | $-1.91 | $-6.72 | — | — | — | — | — | — | — | — | — |
| Net margin | -20.8% | — | -1815.3% | — | -949.6% | -324.3% | -132.5% | -471.9% | -63.6% | -5547.8% | -2579.2% |
| ROIC | — | -50.9% | -154.4% | — | — | — | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is vTv Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 95% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does vTv Therapeutics pay a dividend?
Not currently.
Is vTv Therapeutics a good stock to buy?
We do not give buy or sell advice. vTv Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.